Please assess the completion status of the following clinical trial:

Trial Title: A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* chronic HCV infection~* HCV genotype 2/3 infection~* active injection drug use (within 24 weeks prior to consent) or currently receiving opiate substitution therapy~* compensated liver disease~* negative pregnancy test (within 24 hours of first dose of study medication)~* effective contraception for the duration of the study~* written informed consent~Exclusion Criteria:~* previous interferon or ribavirin therapy~* investigation drug use in the 6 weeks prior to first dose of study medication~* infection with HCV genotypes other than 2/3~* HIV infection~* HBV infection~* ongoing severe psychiatric disease~* frequent drug use that is judged by the treating physician to compromise treatment safety~* standard clinical and medical exclusions for treatment with pegylated interferon alfa 2b and ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Treatment Duration (24 weeks) (Type: ACTIVE_COMPARATOR): Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
- Shortened Treatment Duration (12 Weeks) (Type: EXPERIMENTAL): Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).

Based on this trial design, predict the completion outcome and termination type (if applicable).